BioStock: Aptahem's Scientific Advisors on Sepsis Candidate Apta-1

Aptahem is developing the drug candidate Apta-1 as an emergency treatment for sepsis, a life-threatening condition that is relatively unknown to the general public. BioStock had the opportunity to talk about this and what place Apta-1 might play in future sepsis care with the company’s scientific advisors, Anders Bylock and Mats Eriksson.

 Read the full interview with Anders Bylock and Mats Eriksson at biostock.se:

https://www.biostock.se/en/aptahems-scientific-advisors-on-sepsis-candidate-apta-1/

 This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se